BioScrip Inc (NASDAQ:BIOS) – Analysts at Barrington Research boosted their FY2018 earnings estimates for BioScrip in a research note issued on Monday. Barrington Research analyst M. Petusky now forecasts that the company will post earnings of ($0.22) per share for the year, up from their previous forecast of ($0.23).
Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday. BidaskClub raised shares of BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. ValuEngine raised shares of BioScrip from a “strong sell” rating to a “sell” rating in a report on Thursday, November 9th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $3.00 price target on shares of BioScrip in a report on Friday, November 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $3.63.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). The firm had revenue of $198.70 million for the quarter, compared to the consensus estimate of $202.91 million. During the same period in the previous year, the business posted ($0.12) earnings per share. The company’s revenue for the quarter was down 11.5% compared to the same quarter last year.
In related news, CEO Daniel E. Greenleaf acquired 15,000 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was acquired at an average cost of $2.03 per share, for a total transaction of $30,450.00. Following the transaction, the chief executive officer now directly owns 31,000 shares in the company, valued at $62,930. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.80% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new position in BioScrip during the 3rd quarter worth approximately $114,000. Captrust Financial Advisors acquired a new position in BioScrip during the 2nd quarter worth approximately $123,000. Voya Investment Management LLC increased its position in BioScrip by 41.4% during the 2nd quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock worth $138,000 after purchasing an additional 14,867 shares in the last quarter. Highbridge Capital Management LLC acquired a new position in BioScrip during the 3rd quarter worth approximately $153,000. Finally, Skylands Capital LLC acquired a new position in BioScrip during the 3rd quarter worth approximately $272,000. Institutional investors and hedge funds own 84.63% of the company’s stock.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.